利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

125 条记录 (耗时 0.028 秒)

    Crystalline mixture solid composition and process for preparation thereof
    92.
    发明授权
    Crystalline mixture solid composition and process for preparation thereof 失效
    结晶混合物固体组合物及其制备方法

    公开(公告)号：US06746541B2

    公开(公告)日：2004-06-08

    申请号：US09958666

    申请日：2001-10-12

    申请人： Ryuzo Ueno ,  Akihiko Tabata ,  Junya Honda ,  Yojiro Furukawa ,  Sho Arai

    发明人： Ryuzo Ueno ,  Akihiko Tabata ,  Junya Honda ,  Yojiro Furukawa ,  Sho Arai

    IPC分类号： C13F300

    CPC分类号： C07H1/08 ,  A23L27/34 ,  C40B40/00

    摘要： A crystalline mixture solid composition which has almost no hygroscopicity, is easy to handle and dissolve and hardly worn by abrasion, and comprises &agr;-D-glucopyranosyl-1,1-mannitol and &agr;-D-glucopyranosyl-1,6-sorbitol and may further comprise &agr;-D-glucopyranosyl-1,1-sorbitol in a certain case is obtained in an extremely short period of time by a power-saving and labor-saving process with a small-scale apparatus. A composition which comprises 20 to 75 wt % of &agr;-D-glucopyranosyl-1,1-mannitol, 23 to 70 wt % of &agr;-D-glucopyranosyl-1,6-sorbitol and 2 to 25 wt % of &agr;-D-glucopyranosyl-1,1-sorbitol and is in a crystalline mixture solid state or has a specific surface area of 0.07 to 0.1 m2/g, and a composition which comprises 30 to 75 wt % of &agr;-D-glucopyranosyl-l,1-mannitol, 25 to 70 wt % of &agr;-D-glucopyranosyl-1,6-sorbitol and has a specific surface area of 0.07 to 0.1 m2/g. The above compositions are produced by a process comprising supplying a raw material, which is obtained by optionally removing trehalulose from a mixture containing isomaltulose and trehalulose produced from cane sugar through an isomerization reaction and hydrogenating into a kneader having a thin and long cooling zone together with seed crystals and discharging the obtained composition from an outlet continuously.

    摘要翻译： 具有几乎没有吸湿性的结晶混合物固体组合物易于处理和溶解并且几乎不被磨损磨损，并且包括α-D-吡喃葡萄糖基-1,1-甘露醇和α-D-吡喃葡萄糖基-1,6-山梨糖醇，并且还可以包含α 通过小型装置的省电省力的方法，在极短的时间内可以获得一定的D-吡喃葡萄糖基-1,1-山梨醇.1。一种组合物，其含有20〜75重量％ α-D-吡喃葡萄糖基-1,1-甘露醇，23〜70重量％的α-D-吡喃葡萄糖基-1,6-山梨醇和2〜25重量％的α-D-吡喃葡萄糖基-1,1-山梨醇， 结晶混合物固态或比表面积为0.07〜0.1m 2 / g，组成为30〜75重量％的α-D-吡喃葡萄糖基-1,1-甘露糖醇，25〜70重量％ 的α-D-吡喃葡萄糖基-1,6-山梨糖醇，其比表面积为0.07〜0.1m 2 / g。上述组合物通过包括供给原料的方法制备， 通过任选地通过异构化反应从蔗糖产生的异麦芽酮糖和海藻糖醇的混合物中任选除去海藻糖糖，并将其与晶种一起氢化成具有薄而长的冷却区的捏合机，并连续从出口排出所得组合物。

    Prostaglandin cathartic
    95.
    发明授权
    Prostaglandin cathartic 失效
    前列腺素

    公开(公告)号：US5317032A

    公开(公告)日：1994-05-31

    申请号：US996495

    申请日：1992-12-30

    申请人： Ryuzo Ueno ,  Ryuji Ueno ,  Sachiko Kuno ,  Tomio Oda

    发明人： Ryuzo Ueno ,  Ryuji Ueno ,  Sachiko Kuno ,  Tomio Oda

    IPC分类号： A61K31/557

    CPC分类号： A61K31/557

    摘要： The present invention relates to cathartics comprising 15-keto-16-halogen-PGs as an essential ingredient without substantive side-effects; the catharic effect is thought mainly caused by an enteropooling effect.

    摘要翻译： 本发明涉及包含15-酮-16-卤素-PG作为必需成分而没有实质性副作用的泻药; 念aric效应主要是由于肠道毒作用引起的。

    Method for manufacturing powdery crystalline maltitol
    96.
    发明授权
    Method for manufacturing powdery crystalline maltitol 失效
    粉状结晶麦芽糖醇的制造方法

    公开(公告)号：US5304388A

    公开(公告)日：1994-04-19

    申请号：US32785

    申请日：1993-03-17

    申请人： Ryuzo Ueno ,  Tomoe Kanno ,  Yuji Kunimi ,  Akihiko Tabata

    发明人： Ryuzo Ueno ,  Tomoe Kanno ,  Yuji Kunimi ,  Akihiko Tabata

    IPC分类号： C07H15/04 ,  A23L1/09 ,  A61K31/70

    CPC分类号： C07H15/04 ,  Y10S426/804

    摘要： Disclosure is a method for converting maltitol into crystalline powder by very simple procedures and in short time. To an aqueous solution of maltitol with 1-15% by weight of moisture content, seed crystals of maltitol are added and a shearing force is applied continuously at a temperature lower than the melting point of the seed crystals, thus obtaining a powdery crystalline maltitol.

    摘要翻译： 公开是通过非常简单的程序和短时间将麦芽糖醇转化成结晶粉末的方法。 向具有1-15重量％水分含量的麦芽糖醇的水溶液中加入麦芽糖醇的晶种，并且在低于晶种的熔点的温度下连续施加剪切力，从而获得粉末状的结晶麦芽糖醇。

    Ocular hypotensive agents
    97.
    发明授权
    Ocular hypotensive agents 失效
    眼低血压药

    公开(公告)号：US5236907A

    公开(公告)日：1993-08-17

    申请号：US774750

    申请日：1991-10-11

    申请人： Ryuzo Ueno ,  Ryuji Ueno ,  Tomio Oda

    发明人： Ryuzo Ueno ,  Ryuji Ueno ,  Tomio Oda

    IPC分类号： A61K31/557

    CPC分类号： A61K31/557

    摘要： The present invention relates to an ocular hypotensive treatment of glaucoma which comprising employing 20-substituted-PGs or 20-substituted15-keto-PGs effective as an ocular hypotensive agent; these compounds exhibit no or little side effect such as transient ocular hypertensive response, hyperemia of conjunctiva or of iris, dacryops, lema, closed eye and the like.

    摘要翻译： 本发明涉及青光眼的低血压治疗，其包括使用有效作为眼降压药的20-取代的PG或20-取代的-15-酮-PG; 这些化合物没有或没有副作用，例如暂时性高眼压反应，结膜充血或虹膜，泪囊虫，莱玛，闭眼等。

    Prostaglandins of the F series
    98.
    发明授权
    Prostaglandins of the F series 失效
    F系列前列腺素

    公开(公告)号：US5221763A

    公开(公告)日：1993-06-22

    申请号：US945594

    申请日：1992-09-16

    申请人： Ryuzo Ueno ,  Ryuji Ueno ,  Tomio Oda

    发明人： Ryuzo Ueno ,  Ryuji Ueno ,  Tomio Oda

    IPC分类号： A61K31/557 ,  C07C405/00

    CPC分类号： C07C405/00 ,  A61K31/557

    摘要： The present invention provides new compounds, 13,14-dihydro-15-keto-PGFs, and vassopressors containing them, which raise blood pressure without substantial ephemeral depression of blood pressure, trachea or enteron contraction effect inherent in usual PGFs.

    摘要翻译： 本发明提供了新的化合物，13,14-二氢-15-酮-PGFs和含有它们的旁通加压剂，其可以提高血压，而没有普通PGF固有的血压，气管或肠内收缩作用的实质性短暂抑制。

    Use of 15-ketoprostaglandin E or F compounds for uterine contraction
    99.
    发明授权
    Use of 15-ketoprostaglandin E or F compounds for uterine contraction 失效
    使用15-酮前列腺素E或F化合物进行子宫收缩

    公开(公告)号：US5185374A

    公开(公告)日：1993-02-09

    申请号：US687790

    申请日：1991-04-22

    申请人： Ryuzo Ueno ,  Ryuji Ueno ,  Tomio Oda

    发明人： Ryuzo Ueno ,  Ryuji Ueno ,  Tomio Oda

    IPC分类号： A61K31/557

    CPC分类号： A61K31/557

    摘要： A method of inducing uterine contraction which comprises administering, to a subject in need of such contraction, a uterine-contractionally effective amount of a prostanoic acid derivative selected from the group consisting ofa) 15-ketoprostaglandin E compounds, andb) 15-ketoprostaglandin F compounds with the proviso that when the only one group, which is unsubstituted n-pentyl group, is attached to the carbon atom at the 15-position of the prostanoic acid nucleus and the bond between the carbon atoms at 5- and 6-positions is a double bond, then the bond between the carbon atoms at 13- and 14-positions is a single bond.

    摘要翻译： 一种诱导子宫收缩的方法，其包括向需要这种收缩的受试者施用子宫收缩有效量的选自以下的前列腺酸衍生物：a）15-酮前列腺素E化合物，和b）15-酮前列腺素 F化合物，条件是当仅一个未被取代的正戊基的基团连接到前列腺酸核的15位的碳原子和5-位和6-位的碳原子之间的键时 是双键，则13位和14位的碳原子之间的键是单键。